Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study - Concepedia

Concepedia

Publication | Open Access

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

DOI Full Paper Access

25

Citations

23

References

2016

Year

Ann‐Lii Cheng, Gerardo Cornelio, Lin Shen, Timothy Price, Tsai‐Sheng Yang, Ik Joo Chung, Guang-Hai Dai, Jen-Kou Lin, Atul Sharma, Kun‐Huei Yeh,

Clinical Colorectal Cancer

References

	Year	Citations

Page 1